ObvioHealth, a global leader in digital clinical trial solutions, announced the release of ObvioGo 2.2, the latest version of its innovative platform. This release introduces advanced functionalities designed to streamline study management by leveraging artificial intelligence, enhanced interoperability, and a no-code environment for seamless integration with existing systems and AI models.
HealthTech Insights: Virtuoso Surgical Robot Helps Enable Innovative ARPA-H Project on Artificial Intelligence
ObvioGo 2.2 offers powerful new workflow and task management tools to streamline and enhance trial operations. With real-time compliance tracking and reporting, study teams can proactively identify and address adverse events (AEs), protocol deviations, and compliance risks as they arise, simplifying study management and improving overall efficiency. ObvioGo unified platform, now integrating real-time tracking, reporting, and a centralized data repository, unlocks new and novel AI capabilities. It enables seamless integration with existing AI models and the deployment of agentic functionalities, revolutionizing clinical trial efficiency, compliance, and safety.
HealthTech Insights: Ex-Deep Genomics, Moderna Execs Get Backing Led by Gradient to Develop Next-Generation mRNA Therapeutics with AI
“ObvioGo 2.2 represents a fundamental shift in clinical trial management, setting a new standard for efficiency and innovation” said Ivan Jarry, CEO of ObvioHealth. “By integrating AI-ready capabilities and seamless connectivity, we are redefining operational efficiency and ensuring data and tasks are organized and accessible for study teams. This release sets a new standard for delivering smarter, faster, and more reliable clinical research outcomes.”
HealthTech Insights: Century Health Announces Partnership with Nira Medical to Deliver AI Curated EHR Data for More Than 3,000 Multiple Sclerosis Patients
These enhancements simplify the study manager’s role by organizing tasks and data in real-time, paving the way for more efficient and effective trial management. ObvioGo 2.2 underscores ObvioHealth’s commitment to innovation, positioning the company as a leader in AI-driven clinical trial solutions. With its robust capabilities, the platform meets the growing demand for efficient, scalable, and tech-enabled research solutions, delivering significant value to sponsors and advancing the future of clinical research.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
